Journal article
Elbasvir/Grazoprevir
Hospital pharmacy (Philadelphia), Vol.51(8), pp.665-686
09/2016
Handle:
https://hdl.handle.net/2376/116047
PMCID: PMC5030880
PMID: 27698508
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2016 monograph topics are barictinib, buprenorphine implants, sarilumab, sofosbuvir/velpatasvir, and cholera vaccine, live, oral. The Safey MUE is on sofosbuvir/velpatasvir.
Metrics
15 Record Views
Details
- Title
- Elbasvir/Grazoprevir
- Creators
- Dennis J Cada - The Formulary, College of Pharmacy, Washington State University SpokaneAnne P Kim - Drug Information Resident, College of Pharmacy, Washington State University SpokaneDanial E Baker - Drug Information Center, and College of Pharmacy, Washington State University Spokane
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.51(8), pp.665-686
- Academic Unit
- Pharmacotherapy, Department of
- Identifiers
- 99900547605901842
- Language
- English
- Resource Type
- Journal article